share_log

Senti Biosciences | 8-K: Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights

SEC ·  Mar 20 20:21

Summary by Moomoo AI

Senti Biosciences reported Q4 and FY2024 financial results, highlighting significant clinical progress and strengthened financial position. Two of three relapsed/refractory AML patients treated with SENTI-202 achieved MRD-negative complete remission and maintain remission status. The company successfully raised $47.6M through PIPE financing in December 2024, extending runway into 2026.Q4 2024 financial results showed cash position of $48.3M as of December 31, 2024. R&D expenses decreased to $7.8M from $9.1M YoY, while G&A expenses reduced to $8.4M from $9.3M YoY. Net loss for Q4 was $0.6M ($0.67 per share), with full-year 2024 net loss at $52.8M ($12.03 per share).The company strengthened its leadership team with Jay Cross as CFO and Faraz Siddiqui as SVP of Technical Operations. Additionally, Fran Schulz and Feng Hsiung joined the Board of Directors, bringing expertise in finance and investment management. The company also received $1.5M from CIRM grant, bringing total grant funding to $6.4M.
Senti Biosciences reported Q4 and FY2024 financial results, highlighting significant clinical progress and strengthened financial position. Two of three relapsed/refractory AML patients treated with SENTI-202 achieved MRD-negative complete remission and maintain remission status. The company successfully raised $47.6M through PIPE financing in December 2024, extending runway into 2026.Q4 2024 financial results showed cash position of $48.3M as of December 31, 2024. R&D expenses decreased to $7.8M from $9.1M YoY, while G&A expenses reduced to $8.4M from $9.3M YoY. Net loss for Q4 was $0.6M ($0.67 per share), with full-year 2024 net loss at $52.8M ($12.03 per share).The company strengthened its leadership team with Jay Cross as CFO and Faraz Siddiqui as SVP of Technical Operations. Additionally, Fran Schulz and Feng Hsiung joined the Board of Directors, bringing expertise in finance and investment management. The company also received $1.5M from CIRM grant, bringing total grant funding to $6.4M.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 390

Recommended

Related Stocks Related Stocks
Symbol Mini Chart Price
OSR Holdings
OSRH
3.100
Actinium
ATNM
2.112
Ocean Biomedical
OCEA
0.069
Molecular
MOLN
4.650
Portage Biotech
PRTG
4.640
Log In for the Full List
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina Show More
Can strong earnings reports drive Chinese concept stocks to continue rising?
77%
23%
Bullish
Bearish
1516 votes
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
On Tuesday, China's political leadership is convening at the Great Hall of the People in Beijing for the year's most significant event, known as the "Two Sessions." These closed-door meetings are the annual plenary sessions of both the National People's Congress and the Chinese People's Political Consultative Conference, typically held simultaneously in March. The sessions generally last for about ten days....